Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson's disease models.

Ana I Rodríguez-PérezPablo Garrido-GilMaria García-GarroteAna MuñozJuan A PargaJose Luis Labandeira-GarciaJannette Rodríguez-Pallares

Published in: Stem cell research & therapy (2024)

The results suggest the use of ARBs such as candesartan in PD patients, particularly before and after dopaminergic grafts, and the need to monitor AT1-AA levels in PD patients, particularly in those candidates for dopaminergic grafting.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
spinal cord
patient reported outcomes